echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top 20 best selling tumor drugs in the world (2014-2020)

    Top 20 best selling tumor drugs in the world (2014-2020)

    • Last Update: 2015-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on June 2, 2015, in 2014, the sales scale of three major tumor products of the company, rituximab, Avastin and Herceptin, has reached 21 billion US dollars, while Revlimid, a multiple myeloma drug of Selsyn, will become the first tumor product with sales exceeding 10 billion US dollars in 2020 At this session of the American Society of Clinical Oncology (ASCO), the first generation of checkpoint inhibitors has become the main topic, and has been the focus of the ASCO Conference for three consecutive years Analysts desperately advocate these immune tumor products, which will have bright prospects in the future commercialization The industry has reached a consensus that opdivo, the PD-1 inhibitor launched in BMS last year, is expected to reach US $6.2 billion in annual sales by 2020, while keytruda of MSD is expected to reach US $3.6 billion in annual sales by 2020 There is also a consensus that the other two PD-1 / PD-L1 inhibitors will reach the blockbuster level in 10 years, including Roche's mpdl3280a and AstraZeneca's medi4736, with sales of $2 billion and $1.5 billion respectively The accuracy of these market forecasts remains to be confirmed In this round of ASCO meeting, a new data release caused investors to worry about the commercialization of PD-1 and PD-L1 inhibitor products Investors' voting with their feet directly reduced BMS's estimate by 6.5%, because the company's high hopes checkmate-057 research shows that opdivo, which is used to treat metastatic non-small cell lung cancer (NSCLC), is only effective for those patients with PD-L1 biomarkers, while 40-45% of patients lack relevant biomarkers The research results of checkmate-057 not only raise questions about the commercialization of opdivo in the field of lung cancer treatment, but also bring new questions about BMS's position in the field of lung cancer Even many analysts believe that the research results of checkmate-057 are almost in vain, because the effect of opdivo in the treatment of lung cancer is lower than expected In 2020, the best-selling tumor drug (unit: US $100 million) In the next five years, Roche will become the enterprise with the largest sales volume of tumor products In 2014, the sales scale of the three major tumor products of the company, rituximab, Avastin and Herceptin, has reached US $21 billion, while Revlimid, a multiple myeloma drug of Sergio, will be the first in 2020 Tumor products with annual sales of more than 10 billion US dollars However, Roche is still the leader of tumor market and the super factory of tumor products Although the annual sales of rituximab, Avastin and Herceptin will drop to 16 billion US dollars in 2020, the annual sales of follow-up tumor products such as perjeta, gazyva, kadcyla and mpdl3280a will reach about 10 billion US dollars in 2020 Taking perjeta as an example, the drug will rapidly become a combination of Herceptin and HER2 for treatment The first-line drug for positive breast cancer is expected to have an annual sales volume of more than 4.5 billion US dollars in 2020, while kadcyla is still expected to become the second-line drug for HER2 positive breast cancer even though it can't enter the first-line drug, and the sales volume will also reach the heavy bomb level In 2014, the best-selling cancer drug (unit: US $100 million) Pfizer's breast cancer treatment drug ibrance was approved by FDA earlier this year, and is expected to generate annual sales of about US $4.7 billion in 2020 It is also the fastest-growing cancer product predicted by analysts In addition, the recently approved tumor products with good prospects in the next five years are imbruvica, which is currently promoted and sold jointly by Alberta and Johnson & Johnson Analysts expect the drug to have sales of up to $8 billion by 2020 By 2020, the leading brand cancer drugs we see now may be competing for generic drugs or biological analogues For example, Gleevec of Novartis and Velcade of Johnson & Johnson According to analysts' forecast, the sales volume of Gleevec will decrease from 4.7 billion dollars in 2014 to 570 million dollars in 2020.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.